Mohamed El-Kassas, Marcela Villota-Rivas, Khalid A. Alswat, Khalid M. AlNaamani, Yusuf Yilmaz, Asma Labidi, Faisal M. Sanai, Abeer Awad, Maisam W. I. Akroush, Saleh A. Alqahtani, Mohamed Elbadry, Nermeen Abdeen, Linda Henry, Zobair M. Younossi, Jeffrey V. Lazarus, Abdel-Naser Elzouki, the Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA) Collaborators
{"title":"中东和北非地区代谢功能障碍相关的脂肪变性肝病：制定研究和行动优先议程","authors":"Mohamed El-Kassas, Marcela Villota-Rivas, Khalid A. Alswat, Khalid M. AlNaamani, Yusuf Yilmaz, Asma Labidi, Faisal M. Sanai, Abeer Awad, Maisam W. I. Akroush, Saleh A. Alqahtani, Mohamed Elbadry, Nermeen Abdeen, Linda Henry, Zobair M. Younossi, Jeffrey V. Lazarus, Abdel-Naser Elzouki, the Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA) Collaborators","doi":"10.1111/liv.70108","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background & Aims</h3>\n \n <p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing health challenge, particularly in Middle East and North Africa (MENA) countries. This study aimed to establish a consensus-driven research and action agenda to address MASLD within the MENA region.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Following a global MASLD research and action agenda setting study, over two Delphi rounds (Rs), MENA region experts (R1 <i>n</i> = 112, R2 <i>n</i> = 104) indicated their level of agreement with and provided feedback on MASLD research and action priorities via Qualtrics XM. In R2, panellists also ranked the priorities, which were categorised across six domains: (1) the human and economic burden, (2) defining and implementing care models, (3) disease management, (4) education and awareness, (5) patient and community perspectives, and (6) leadership and policies for the MASLD public health agenda.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The consensus-built MASLD research and action priority agenda for the MENA region comprises 52 priorities. Combined agreement (i.e., ‘agree’ + ‘somewhat agree’) increased from 97.6% and 98.1% in R1 to 98.2% and 98.5% in R2 with the research (<i>n</i> = 30) and action (<i>n</i> = 22) priorities, respectively. The highest ranked research priorities included developing regional MASLD databases and validating non-invasive diagnostic tools. The highest ranked action priorities included taking steps to enhance the adoption of lifestyle interventions among people living with MASLD and improving disease knowledge among healthcare providers.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This region-specific agenda can help to guide research and optimise clinical practice, thereby improving the understanding, prevention, and management of MASLD, enhancing health outcomes and reducing its burden within the MENA region.</p>\n </section>\n </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 6","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metabolic Dysfunction-Associated Steatotic Liver Disease in the MENA Region: Setting a Research and Action Priority Agenda\",\"authors\":\"Mohamed El-Kassas, Marcela Villota-Rivas, Khalid A. Alswat, Khalid M. AlNaamani, Yusuf Yilmaz, Asma Labidi, Faisal M. Sanai, Abeer Awad, Maisam W. I. Akroush, Saleh A. Alqahtani, Mohamed Elbadry, Nermeen Abdeen, Linda Henry, Zobair M. Younossi, Jeffrey V. Lazarus, Abdel-Naser Elzouki, the Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA) Collaborators\",\"doi\":\"10.1111/liv.70108\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background & Aims</h3>\\n \\n <p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing health challenge, particularly in Middle East and North Africa (MENA) countries. This study aimed to establish a consensus-driven research and action agenda to address MASLD within the MENA region.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Following a global MASLD research and action agenda setting study, over two Delphi rounds (Rs), MENA region experts (R1 <i>n</i> = 112, R2 <i>n</i> = 104) indicated their level of agreement with and provided feedback on MASLD research and action priorities via Qualtrics XM. In R2, panellists also ranked the priorities, which were categorised across six domains: (1) the human and economic burden, (2) defining and implementing care models, (3) disease management, (4) education and awareness, (5) patient and community perspectives, and (6) leadership and policies for the MASLD public health agenda.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The consensus-built MASLD research and action priority agenda for the MENA region comprises 52 priorities. Combined agreement (i.e., ‘agree’ + ‘somewhat agree’) increased from 97.6% and 98.1% in R1 to 98.2% and 98.5% in R2 with the research (<i>n</i> = 30) and action (<i>n</i> = 22) priorities, respectively. The highest ranked research priorities included developing regional MASLD databases and validating non-invasive diagnostic tools. The highest ranked action priorities included taking steps to enhance the adoption of lifestyle interventions among people living with MASLD and improving disease knowledge among healthcare providers.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>This region-specific agenda can help to guide research and optimise clinical practice, thereby improving the understanding, prevention, and management of MASLD, enhancing health outcomes and reducing its burden within the MENA region.</p>\\n </section>\\n </div>\",\"PeriodicalId\":18101,\"journal\":{\"name\":\"Liver International\",\"volume\":\"45 6\",\"pages\":\"\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Liver International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/liv.70108\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/liv.70108","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景,代谢功能障碍相关的脂肪变性肝病（MASLD）是一个日益严重的健康挑战，特别是在中东和北非（MENA）国家。这项研究旨在建立一个共识驱动的研究和行动议程，以解决中东和北非地区的MASLD问题。方法在一项全球MASLD研究和行动议程设置研究之后，经过两轮德尔菲(r)，中东和北非地区专家（R1 n = 112, R2 n = 104）表明了他们对MASLD研究和行动重点的同意程度，并通过qualqualics XM提供了反馈。在R2中，小组成员还对优先事项进行了排序，这些优先事项分为六个领域：(1)人力和经济负担，(2)定义和实施护理模式，(3)疾病管理，(4)教育和意识，(5)患者和社区观点，以及(6)MASLD公共卫生议程的领导和政策。结果建立共识的中东和北非地区研究和行动优先议程包括52个优先事项。对于研究（n = 30）和行动（n = 22）优先级，综合同意（即“同意”+“有点同意”）分别从R1中的97.6%和98.1%增加到R2中的98.2%和98.5%。排名最高的研究重点包括开发区域MASLD数据库和验证非侵入性诊断工具。排名最高的行动优先事项包括采取步骤，在MASLD患者中更多地采用生活方式干预措施，并改善保健提供者的疾病知识。这一区域特定议程有助于指导研究和优化临床实践，从而提高对MASLD的认识、预防和管理，提高健康结果，减轻中东和北非地区的负担。
Metabolic Dysfunction-Associated Steatotic Liver Disease in the MENA Region: Setting a Research and Action Priority Agenda
Background & Aims
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing health challenge, particularly in Middle East and North Africa (MENA) countries. This study aimed to establish a consensus-driven research and action agenda to address MASLD within the MENA region.
Methods
Following a global MASLD research and action agenda setting study, over two Delphi rounds (Rs), MENA region experts (R1 n = 112, R2 n = 104) indicated their level of agreement with and provided feedback on MASLD research and action priorities via Qualtrics XM. In R2, panellists also ranked the priorities, which were categorised across six domains: (1) the human and economic burden, (2) defining and implementing care models, (3) disease management, (4) education and awareness, (5) patient and community perspectives, and (6) leadership and policies for the MASLD public health agenda.
Results
The consensus-built MASLD research and action priority agenda for the MENA region comprises 52 priorities. Combined agreement (i.e., ‘agree’ + ‘somewhat agree’) increased from 97.6% and 98.1% in R1 to 98.2% and 98.5% in R2 with the research (n = 30) and action (n = 22) priorities, respectively. The highest ranked research priorities included developing regional MASLD databases and validating non-invasive diagnostic tools. The highest ranked action priorities included taking steps to enhance the adoption of lifestyle interventions among people living with MASLD and improving disease knowledge among healthcare providers.
Conclusions
This region-specific agenda can help to guide research and optimise clinical practice, thereby improving the understanding, prevention, and management of MASLD, enhancing health outcomes and reducing its burden within the MENA region.
期刊介绍：
Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
